

was calculated from the parabolic fitting on the MSD curves was 457 nm/s. This value is 10 times faster than velocity of microtubules, 50.3 nm/s.

MSD analysis describes the overall behavior of the molecules but does not provide detailed information about the movement. To investigate the detailed behavior of the dynamics of microtubules and kinesins, each trajectory in longitudinal (*X* direction) and transverse direction (*Y* direction) of microtubule was analyzed. Fig. 4 shows an example of the trajectory analysis for microtubules and kinesin molecules. The first column (Figs. 4A1, B1 and C1) shows the plots of the *x* and *y* positions versus time. The plus value of the *x* position means movement away from the nucleus or towards the plus end of the microtubule. While there is a large change in the position of *x*, the change of *y* position is relatively small in both the microtubule and the kinesin, indicating the movement is linear. However the direction of movement of the microtubules was changed more often than that of the kinesin.

The velocity averaged for the period of 0.5 s revealed a characteristic movement of kinesin in living cells (Figs. 4A2, B2, C2). As shown in Fig. 4B2, kinesin came to an almost stop ($V_x < 100$ nm/s), paused for a few seconds and then moved once again. This pause in the movement was observed in all the kinesin traces in 20 kinesin-QD conjugates in 5 cells. To compare the velocity of kinesin in cells with that in the *in vitro* assay, the kinesin-QDs were interacted with microtubules fixed on a coverslip and the movement of kinesin was observed under a total reflection fluorescence microscope [3]. Kinesin in the *in vitro* assay moved smoothly with an almost constant velocity (Fig. 4C) and they seldom stopped for more than a few seconds. The difference between the velocity of kinesin in cells and the *in vitro* is clearly demonstrated in the histograms of Figs. 4B3 and C3: high frequency at low velocity <100 nm/s in cells but low frequency in the *in vitro*. This result indicates that the "stop and go" behavior of kinesin is a unique phenomenon that occurs in the only cells but not in the *in vitro* assay. The "stop and go" behavior of kinesin is similar to previous reports of the vesicle transport by dynein in cultured cells and mice tumor cells [13,30]. Our data, however, is inconsistent with a previous report that the distributions of kinesin velocity in cells and *in vitro* are remarkably similar [21]. The difference could be due to the difference species of kinesin, mouse kinesin-1 in this study and drosophila kinesin-1 in the previous work. It could also be possible that movement of mouse kinesin is regulated by microtubule associated proteins such as tau which inhibits kinesin movement presumably by steric blocking [13,31,32].

Discrepancies were also found between the velocities of kinesin in cells and in the *in vitro* assay. The maximum velocity of kinesin in cells was 1.5–2.4 $\mu\text{m/s}$ observed with the small portion in velocity of kinesin (Fig. 4B2). The maximum velocity of kinesin in the *in vitro* assay was up to 1.2 $\mu\text{m/s}$ which is considerably slower than that in cells (Fig. 4C2). A simple explanation for this discrepancy is that the apparent velocity of kinesin in cells includes the velocity of the microtubules. Interestingly, the maximum speed that vesicles move in a living cell is often significantly higher than kinesin motors measured in *in vitro* systems [33,34]. Our results suggest that the fast movement of vesicles is related to the dynamics of both kinesin and microtubules. Identifying the unique behavior of the motor proteins in living cell is an important goal to understand intracellular traffics and cell division for future work.

Bio-conjugated QDs were successfully delivered into cells, and hundreds of single QDs were tracked for long periods of time. Our work also shows that the antibody and kinesin did not lose their function within living cells, suggesting that this new method is also applicable for investigation of other proteins. The major advantage of this method is that it is possible to track single QDs with bright fluorescence within living cells for long periods of time with high temporal and spatial resolution. The next step will be to observe the movement with higher precision, sub-milliseconds and 1 nm, within living cells to investigate natural function and molecular mechanism of the proteins [13,27,34]. Another approach will be to image several different of molecules within single cells at the same time. The general method described here is an excellent method for intracellular targeting proteins and for investigation of behavior of purified protein. This approach opens new avenues for studying living cells in biology and medical science.

Acknowledgments

We gratefully acknowledge J.M. West for critical reading of this manuscript. This work was supported by Grants-in-Aid for Scientific Research in Priority Areas from the Japan MEXT (H.H.), and Special Coordination Funds for Promoting Science and Technology of JST (H.H. and K.G.) and CREST of JST (H.H.).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at doi:10.1016/j.yexcr.2008.09.014.

REFERENCES

- [1] A. Ishijima, T. Yanagida, Single molecule nanobiotechnology, Trends Biochem. Sci. 26 (2001) 438–444.
- [2] S. Toba, T.M. Watanabe, L. Yamaguchi-Okimoto, Y.Y. Toyoshima, H. Higuchi, Overlapping hand-over-hand mechanism of single molecular motility of cytoplasmic dynein, Proc. Natl. Acad. Sci. 103 (2006) 5741–5745.
- [3] R.D. Vale, T. Funatsu, D.W. Pierce, L. Romberg, Y. Harada, T. Yanagida, Direct observation of single kinesin molecules moving along microtubules, Nature 380 (1996) 451–453.
- [4] A. Yildiz, J.N. Forkey, S.A. McKinney, T. Ha, Y.E. Goldman, P.R. Selvin, Myosin V walks hand-over-hand: single fluorophore imaging with 1.5-nm localization, Science 300 (2003) 2061–2065.
- [5] Y. Sako, T. Yanagida, Single-molecule visualization in cell biology, Nat. Rev. Mol. Cell Biol. Suppl (2003) S51–S55.
- [6] X.S. Xie, J. Yu, W.Y. Yang, Living cells as test tubes, Science 312 (2006) 228–230.
- [7] M. Bruchez Jr, M. Moronne, A.P. Alivisatos, Semiconductor nanocrystals as fluorescent biological labels, Science 281 (1998) 2013.
- [8] W.C.W. Chan, S. Nie, Quantum dot bioconjugates for ultrasensitive nonisotopic detection, Science 281 (1998) 2016–2018.
- [9] J.K. Jaiswal, H. Mattoussi, J.M. Mauro, S.M. Simon, Long-term multiple color imaging of live cells using quantum dot bioconjugates, Nat. Biotechnol. 21 (2003) 47–51.
- [10] S. Li-Shihido, T.M. Watanabe, H. Tada, H. Higuchi, N. Ohuchi, Reduction in nonfluorescence state of quantum dots on an

- immunofluorescence staining, *Biochem. Biophys. Res. Commun.* 351 (2006) 7–13.
- [11] X. Wu, H. Liu, J. Liu, K.N. Haley, J.A. Treadway, J.P. Larson, N. Ge, F. Peale, M.P. Bruchez, Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots, *Nat. Biotechnol.* 21 (2003) 41–46.
- [12] D.S. Lidke, P. Nagy, R. Heintzmann, D.J. Arndt-Jovin, J.N. Post, H.E. Grecco, E.A. Jares-Erijman, T.M. Jovin, Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction, *Nat. Biotechnol.* 22 (2004) 198–203.
- [13] T.M. Watanabe, H. Higuchi, Stepwise movements in vesicle transport of HER2 by motor proteins in living cells, *Biophys. J.* 92 (2007) 4109–4120.
- [14] M. Dahan, S. Levi, C. Luccardini, P. Rostaing, B. Riveau, A. Triller, Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking, *Science* 302 (2003) 442–445.
- [15] I.L. Medintz, H.T. Uyeda, E.R. Goldman, H. Mattoussi, Quantum dot bioconjugates for imaging, labelling and sensing, *Nat. Mater.* 4 (2005) 435–446.
- [16] K.-S. Huang, Y.-C. Lin, K.-C. Su, H.-Y. Chen, An electroporation microchip system for the transfection of zebrafish embryos using quantum dots and GFP genes for evaluation, *Biomed. Microdevices* 9 (2007) 761–768.
- [17] A.M. Derfus, W.C.W. Chan, S.N. Bhatia, Intracellular delivery of quantum dots for live cell labeling and organelle tracking, *Adv. Mater.* 16 (2004) 961–966.
- [18] E.B. Voura, J.K. Jaiswal, H. Mattoussi, S.M. Simon, Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy, *Nat. Med.* 10 (2004) 993–998.
- [19] H. Duan, S. Nie, Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings, *J. Am. Chem. Soc.* 129 (2007) 3333–3338.
- [20] A. Hoshino, K. Fujioka, T. Oku, S. Nakamura, M. Suga, Y. Yamaguchi, K. Suzuki, M. Yasuhara, K. Yamamoto, Quantum dots targeted to the assigned organelle in living cells, *Microbiol. Immunol.* 48 (2004) 985–994.
- [21] S. Courty, C. Luccardini, Y. Bellaiche, G. Cappello, M. Dahan, Tracking individual kinesin motors in living cells using single quantum-dot imaging, *Nano Lett.* 6 (2006) 1491–1495.
- [22] D. Kutz, M. Burg, Evolution of osmotic stress signaling via MAP kinase cascades, *J. Exp. Biol.* 201 (1998) 3015–3021.
- [23] L. Wasungu, D. Hoekstra, Cationic lipids, lipoplexes and intracellular delivery of genes, *J. Control. Release* 116 (2006) 255–264.
- [24] A. Kusumi, C. Nakada, K. Ritchie, K. Murase, K. Suzuki, H. Murakoshi, R.S. Kasai, J. Kondo, T. Fujiwara, Paradigm shift of the plasma membrane concept from the two-dimensional continuum fluid to the partitioned fluid: High-speed single-molecule tracking of membrane molecules, *Annu. Rev. Biophys. Biomol. Struct.* 34 (2005) 351–378.
- [25] W.J. Parak, R. Boudreau, M.L. Gros, D. Gerion, D. Zanchet, C.M. Micheel, S.C. Williams, A.P. Alivisatos, C. Larabell, Cell motility and metastatic potential studies based on quantum dot imaging of phagokinetic tracks, *Adv. Mater.* 14 (2002) 882–885.
- [26] J. Howard, *Mechanics of Motor Proteins and the Cytoskeleton*, Sinauer Associates, 2001.
- [27] X. Nan, P.A. Sims, P. Chen, X.S. Xie, Observation of individual microtubule motor steps in living cells with endocytosed quantum dots, *J. Phys. Chem. B* 109 (2005) 24220–24224.
- [28] J. Howard, A.J. Hudspeth, R.D. Vale, Movement of microtubules by single kinesin molecules, *Nature* 342 (1989) 154–158.
- [29] A. Yildiz, M. Tomishige, R.D. Vale, P.R. Selvin, Kinesin walks hand-over-hand, *Science* 303 (2004) 676–678.
- [30] H. Tada, H. Higuchi, T.M. Watanabe, N. Ohuchi, In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice, *Cancer Res.* 67 (2007) 1138–1144.
- [31] R. Dixit, J.L. Ross, Y.E. Goldman, E.L.F. Holzbaur, Differential regulation of dynein and kinesin motor proteins by tau, *Science* 319 (2008) 1086–1089.
- [32] B. Trinczek, A. Ebneth, E.M. Mandelkow, E. Mandelkow, Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles, *J. Cell. Sci.* 112 (1999) 2355–2367.
- [33] D.B. Hill, M.J. Plaza, K. Bonin, G. Holzwarth, Fast vesicle transport in PC12 neurites: velocities and forces, *Eur. Biophys. J.* 33 (2004) 623–632.
- [34] C. Kural, H. Kim, S. Syed, G. Goshima, V.I. Gelfand, P.R. Selvin, Kinesin and dynein move a peroxisome in vivo: a tug-of-war or coordinated movement? *Science* 308 (2005) 1469–1472.



ZnO clusters: Laser ablation production and time-of-flight mass spectroscopic study

A. Dmytruk^{a,d,*}, I. Dmitruk^{b,d}, I. Blonsky^a, R. Belosludov^c, Y. Kawazoe^c, A. Kasuya^d

^a Institute of Physics of National Academy of Sciences of Ukraine, Kyiv 03028, Ukraine

^b Physics Department, National Taras Shevchenko University of Kyiv, Kyiv 03122, Ukraine

^c Institute for Materials Research, Tohoku University, Sendai 980-8577, Japan

^d Center for Interdisciplinary Research, Tohoku University, Sendai 980-8578, Japan

ARTICLE INFO

Available online 9 September 2008

Keywords:

Zinc oxide

Cluster

Magic number

Time-of-flight mass spectroscopy

ABSTRACT

Zinc oxide clusters have been produced by laser ablation of bulk powder zinc peroxide in vacuum and investigated by time-of-flight mass spectroscopy. Experimental results revealed unpredicted and hitherto unknown $(\text{ZnO})_n$ clusters of enhanced stability ("magic clusters") at $n = 34, 60$ and 78 . Cage-like structures for the magic clusters have been suggested, supported by first-principles calculations.

© 2008 Elsevier Ltd. All rights reserved.

1. Introduction

Decrease of the size of functional elements is the mainstream of microelectronics industry evolution. Reaching the nanometer scale, however, the properties of objects are determined not only by their composition, but also by their size, shape and structure. Drastic changes of material properties appear in transition region between solid state and atoms (molecules), i.e. in the range below about 200 monomers (constituting elements). Clusters of this range have a practical value only if they possess an enhanced stability ("magic clusters"), like the well-known carbon fullerenes [1], or the recently discovered CdSe magic particles [2]. The other advantage of magic clusters is the atomic precision of their composition that considerably simplifies experimental research on nanomaterials and much spreads their applications, especially when a regular arrangement of nanostructures is necessary. Among others, ZnO is of interest as a promising material for photovoltaics, optoelectronics, spintronics, photoelectrochemistry and others, and deserves special attention for biomedical applications, as it is low toxic. The exciton Bohr radius of ZnO is about 1.8 nm, meaning that strong quantum confinement effects could be observed for clusters consisting of less than a 1000 of ZnO monomers, approximately, if we consider cluster's density the same as for bulk material that emphasizes the interest to the small $(\text{ZnO})_n$ clusters.

A possibility for ZnO to form spheroids (fullerenes) has been predicted theoretically, suggesting $n = 12$ and 16 as the magic numbers [3], and stable three-dimensional spheroid structures for $n = 8, 9$ and larger [4]. Zn_2O_2 and Zn_3O_3 rings have been

suggested as building blocks for larger spheroid clusters. Recent studies [5] extended the range of calculated ZnO clusters up to $n = 64$; however, not all the clusters in the range have been studied, but $n = 9-16, 18, 20, 22, 24, 28, 36, 48$ and 64 only. It has been shown that "bubble-like" cluster structure is energetically more favorable than the wurtzite structure for $n < 26$, while the wurtzite structure is more stable for $n \geq 26$ and larger clusters. Also, the "onion-like" cluster $(\text{ZnO})_{60}$, constructed by putting $(\text{ZnO})_{12}$ cage inside of $(\text{ZnO})_{48}$ cage, has been shown to be more stable than $(\text{ZnO})_{64}$ bubble-like cluster by about 0.2 eV/atom. Very recently, it has been reported that the onion-like and bulk-like isomers are progressively more stable with increasing size, but cage and tube structures are the most preferred structural motifs for $(\text{ZnO})_n$ with $n = 24, 28, 36$ and 48 [6]. Thus, the extensive calculations done still do not cover the whole range of small ZnO clusters, and their results partially contradict each other.

A large number of extensive experimental studies were done on zinc oxide (ZnO) nanoparticles of several nanometers and larger scale, containing hundreds and much more of ZnO monomers. However, only a few papers deal with small $(\text{ZnO})_n$ clusters, and they all are limited to $n < 20$ only. Typically, the clusters were produced by laser ablation of ZnO powder in vacuum, and no magic numbers were found in mass spectra [7,8]. Recent studies on synthesized by electroporation of vesicles, uncapped small $(\text{ZnO})_n$ clusters showed oscillating red and blue shifts of the characteristic absorption band from $n = 1$ to 15 , while no peculiarities were observed for $n > 15$ [9]. Overall, both experimental and theoretical studies of $(\text{ZnO})_n$ clusters of $n > 20$ with the atomic precision are scarce.

Here, we present time-of-flight (TOF) mass spectroscopic studies on ZnO clusters of up to about a hundred of monomers,

* Corresponding author at: Institute of Physics of National Academy of Sciences of Ukraine, Kyiv 03028, Ukraine. Fax: +38044 5251543.

E-mail address: admytruk@gmail.com (A. Dmytruk).

and propose possible structures for the extra stable clusters, supported by extensive first-principles calculations.

2. Experimental

ZnO clusters were formed by laser ablation of bulk powder zinc peroxide (ZnO_2) in a Bruker Reflex III-T TOF mass spectrometer. ZnO_2 powder (WAKO) was mixed with a small amount of solvent (distilled water or toluene), and with alkylamine matrix (decylamine or dodecylamine, WAKO) in some experiments. About $1 \mu\text{l}$ of the resulting suspension was dropped on a stainless steel target, dried in vacuum, and the target was inserted in the mass spectrometer. The spectrometer was equipped with a nitrogen laser, which produced 4 ns pulses of 337.1 nm wavelength light with $300 \mu\text{J}$ energy at 1–3 Hz repetition rate. The laser beam was passed through a controlled attenuator (typically about 10% attenuation level was used) and focused into about $20 \mu\text{m}$ spot on the target. Cooling by carrier gas injection was not used. Produced ions were accelerated by a potential of 19 kV, separated in the flight tube either in linear or in reflex mode, and registered by a microchannel plate detector. Positively or negatively charged clusters were measured, depending on the polarity of the accelerating potential. Typically the reflex mode was used, and the spectrum was acquired by accumulating the signal of about 500 laser shots.

3. Results and discussion

ZnO_2 has essentially different properties from ZnO, namely a much lower thermolysis temperature (150 °C for ZnO_2 and 1975 °C for ZnO) and density (1570 and 5600 kg/m^3 , respectively). The differences indicate much weaker interatomic bonds in ZnO_2 than in ZnO. Practically, that makes ZnO_2 powder a much more efficient precursor for ZnO clusters than the ZnO powder used in previous laser ablation experiments [7,8]. The excess oxygen in ZnO_2 may volatilize during laser ablation. Therefore, using of ZnO_2 is a crucial factor for efficient production of ZnO clusters by laser ablation.

Fig. 1 shows a TOF mass spectrum of positively charged clusters obtained by laser ablation of ZnO_2 powder. The spectrum consists of a series of peaks separated by about 81.42 amu, which corresponds to the mass of ZnO (81.39 amu). The complete series of $(\text{ZnO})_n$ clusters can be reliably resolved up to more than a hundred of ZnO monomers. $(\text{ZnO})_{34}$, $(\text{ZnO})_{60}$, and $(\text{ZnO})_{78}$ clusters are significantly more abundant than their neighbors in the series, that allows to call them "magic clusters". $(\text{ZnO})_{60}$ is the most remarkable among them. Although it is difficult to compare quantitatively the occurrence of magic and non-magic clusters produced and studied in this experiment, the observed small advantage of the magic clusters could result in significant dominance of these clusters being produced by some other methods. For example, TOF mass spectra of carbon clusters obtained by laser ablation of graphite [10] and other carbon compounds [11] show just slightly higher occurrences of C_{60} clusters than of the others, while optimization of cluster formation conditions allowed much more effective C_{60} production [1].

The reported results of calculations on ZnO clusters are scarce for the observed magic numbers, therefore applicable models of other binary compounds should be considered to suggest the structures for ZnO. The closest allies are other II–VI and III–V group compounds. Among them, CdSe and BN clusters are the best studied.

As ZnO belongs to II–VI group, it is no wonder to find in ZnO series the magic cluster of 34 monomers which found commonly for other group members (ZnS, ZnSe, ZnTe, CdS, CdSe, CdTe) [10], and to suppose its structure is the same as the structure of the well-studied $(\text{CdSe})_{34}$ [2].

The magic cluster of 60 monomers was not experimentally observed hitherto either for II–IV or for III–V group compounds. However, some theoretical studies have been performed: an onion-like structure has been calculated recently for $(\text{ZnO})_{60}$ [5], whilst the empty cage has been suggested earlier for $(\text{BN})_{60}$ [12]. Our ongoing extensive first-principles calculations nominate the $(\text{ZnO})_{12} @ (\text{ZnO})_{48}$ nested cage as the most stable isomer of $(\text{ZnO})_{60}$.

The structure of $(\text{ZnO})_{78}$ magic cluster is not clear yet. Presumably, it consists of six $(\text{ZnO})_{12}$ clusters joined by 6 extra ZnO pairs, or of 6 $(\text{ZnO})_{14}$ clusters with 6 common ZnO pairs, or of




Fig. 1. TOF mass spectrum of ZnO clusters.

6 (ZnO)₁₃ clusters which are extremely stable for other II–VI group compounds [10]. Further calculations of the isomers will show the most stable structure for the cluster.

4. Conclusion

Using of ZnO₂ precursor allowed obtaining the mass spectrum of ZnO clusters of up to about a hundred of monomers. The spectrum clearly shows a set of magic clusters neither observed nor predicted hitherto: (ZnO)₃₄, (ZnO)₆₀ and (ZnO)₇₈. It is supposed, that the magic cluster of 34 monomers has the same core-cage structure as (CdSe)₃₄ [2] that found commonly for the other II–VI group compounds [10], whilst the magic cluster of 60 monomers most probably has the structure of (ZnO)₁₂ @ (ZnO)₄₈ nested cage. Results of our extensive first-principles calculations of the proposed cluster structures prove their stability.

The laser ablation method produces ZnO clusters with structures inaccessible yet by other synthesis methods. We believe that our findings of ZnO clusters of enhanced stability will help to develop methods of their production in mass quantities. The enhanced stability of the rather large (ZnO)₆₀ cluster may be especially useful for applications, where the atomic precision of about 1 nm scale inorganic semiconductor nanoparticles is necessary.

References

- [1] H.W. Kroto, J.R. Heath, S.C. O'Brien, R.F. Curl, R.E. Smalley, C60: Buckminsterfullerene, *Nature* 318 (1985) 162–163.
- [2] A. Kasuya, R. Sivamohan, Yu.A. Barnakov, I.M. Dmitruk, T. Nirasawa, V.R. Romanyuk, et al., Ultra-stable nanoparticles of CdSe revealed from mass spectrometry, *Nat. Mater.* 3 (2004) 99–102.
- [3] E.C. Behrman, R.K. Foehrweiser, J.R. Myers, B.F. French, M.E. Zandler, Possibility of stable spheroid molecules of ZnO, *Phys. Rev. A* 49 (1994) R1543–R1546.
- [4] J.M. Matxain, J.E. Fowler, J.M. Ugalde, Small clusters of II–VI materials: Zn_nO_i, $i = 1–9$, *Phys. Rev. A* 62 (2000) 053201–053210.
- [5] M. Zhao, Y. Xia, Z. Tan, X. Liu, L. Mei, Design and energetic characterization of ZnO clusters from first-principles calculations, *Phys. Lett. A* 372 (2007) 39–43.
- [6] B. Wang, X. Wang, G. Chen, S. Nagase, J. Zhao, Cage and tube structures of medium-sized zinc oxide clusters (ZnO)_n ($n = 24, 28, 36$ and 48), *J. Chem. Phys.* 128 (2008) 144710.
- [7] A. Burmin, J.J. BelBruno, Zn_nS_m cluster production by laser ablation, *Chem. Phys. Lett.* 362 (2002) 341–348.
- [8] I.M. Kukreja, A. Rohlfing, P. Misra, F. Hillenkamp, K. Dreisewerd, Cluster formation in UV laser ablation plumes of ZnSe and ZnO studied by time-of-flight mass spectrometry, *Appl. Phys. A* 78 (2004) 641–644.
- [9] S. Wu, N. Yuan, H. Xu, X. Wang, Z. A. Schelly, Synthesis and bandgap oscillation of uncapped, ZnO clusters by electroporation of vesicles, *Nanotechnology* 17 (2006) 4713–4718.
- [10] V. Romanyuk, I. Dmitruk, Yu. Barnakov, R. Belosludov, A. Kasuya, Ultra-stable nanoparticles in A₂B₄ (A₂ = Cd, Zn; B₄ = Se, S, Te) compounds, *J. Nanosci. Nanotechnol.* to appear.
- [11] O. Sedo, M. Alberti, J. Janca, J. Havel, Laser desorption–ionization time of flight mass spectrometry of various carbon materials, *Carbon* 44 (2006) 840–847.
- [12] V.V. Pokropivny, V.V. Skorokhod, G.S. Oleinik, A.V. Kurdyumov, T.S. Bartnitskaya, A.V. Pokropivny, et al., Boron nitride analogs of fullerenes (the fulborenes), nanotubes, and fullerites (the fulborenes), *J. Solid State Chem.* 154 (2000) 214–222.

Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes

Takanori Ishida · Takayoshi Kiba · Motohiro Takeda · Kotone Matsuyama · Satoshi Teramukai · Ryota Ishiwata · Norikazu Masuda · Yuichi Takatsuka · Shinzaburo Noguchi · Chikashi Ishioka · Masanori Fukushima · Noriaki Ohuchi

Received: 27 August 2008 / Accepted: 20 November 2008
© The Author(s) 2008. This article is published with open access at Springerlink.com

Abstract

Purpose The purpose of this study was to investigate the activity of capecitabine and trastuzumab in patients with HER2-overexpressing metastatic breast cancer resistant to both anthracyclines and taxanes.

Method From June 2003 and May 2006, 40 female patients with measurable or assessable metastatic breast cancer were enrolled and data from 38 patients were reviewed extramurally and analyzed. Patients were treated

with weekly trastuzumab given at a dose of 2 mg/kg/day over 90 min (4 mg/kg/day on the first infusion) and capecitabine given at a dose 1,657 mg/m²/day during 21 days with a subsequent pause of 7 days. This cycle was repeated every 28 days. The primary endpoint was overall survival and secondary endpoints were progression-free survival and response rate.

Result A median of 4.5 cycles (range 1–9 cycles) were delivered. The median age was 53 (range 30–69 years). Median overall survival and progression-free survival was 22.3 and 4.1 months, respectively. Survival rate at 1 and 2 year was 81.6 and 47.4%, respectively. Response rate was 18.4% (95% CI, 7.7–34.3%). All evaluable patients have responded with two CR (5.3%), 5 PR (13.2%), 20 SD (52.6%), 8 PD (21.1%) and 3 NE (7.9%). Regarding the hematological toxicities, grade 1/2/3 neutropenia, grade 1/2 anemia, grade 1 thrombocytopenia and grade 1/2 liver dysfunction were also common. No treatment-related death was reported.

Conclusion The combination of capecitabine and trastuzumab is active and well-tolerated in patients with HER2-overexpressing breast cancer resistant to both anthracyclines and taxanes.

T. Ishida · M. Takeda · N. Ohuchi (✉)
Department of Surgical Oncology,
Tohoku University School of Medicine,
1-1 Seiryō-machi, Aoba-ku, Sendai 980-8574, Japan
e-mail: noriakio@mail.tains.tohoku.ac.jp

T. Kiba · K. Matsuyama · S. Teramukai · R. Ishiwata ·
M. Fukushima
Translational Research Informatics Center, Kobe, Japan

K. Matsuyama · S. Teramukai · M. Fukushima
Department of Clinical Trial Design and Management,
Graduate School of Medicine, Kyoto University,
Kyoto, Japan

N. Masuda
Department of Surgery, Osaka National Hospital, Osaka, Japan

Y. Takatsuka
Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan

S. Noguchi
Department of Breast and Endocrine Surgery,
Graduate School of Medicine, Osaka University,
Osaka, Japan

C. Ishioka
Department of Clinical Oncology,
Institute of Developing, Aging and Cancer,
Tohoku University, Sendai, Japan

Keywords Phase II study · Capecitabine · Trastuzumab
Metastatic breast cancer

Abbreviations

BCIRG	Breast Cancer International Research Group
CI	Confidence interval
CMF	Cyclophosphamide, methotrexate and fluorouracil
ECOG	Eastern Cooperative Oncology Group
ER	Estrogen receptor
FU	Fluorouracil

HER2	Epidermal growth factor receptor 2
IHC	Immunohistochemistry
FISH	Fluorescence in situ hybridization
MUGA	Multigated acquisition
PgR	Progesterone receptor
RECIST	Response evaluation criteria in solid tumors

Introduction

Despite improvements in survivability of nonmetastatic breast cancer patients over the past 25 years, particularly for both estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-positive disease, metastatic breast cancer remains an incurable disease [1, 2]. When the disease recurred, the decision to choose a certain therapy is usually based on tumor biology, symptoms, metastatic pattern, time to disease recurrence, and patient desire [3].

For metastatic breast cancer the initial treatment with anthracycline-based chemotherapy and/or taxane-based therapy is considered as standard [4, 5], whereas the outcome is still poor at present. Therefore, the new avenue for breakthrough in treatments is required to provide. One of the possible approaches is to use molecular targeting therapy. Breast cancers that make high levels of the transmembrane protein kinase HER2 (i.e., those that overexpress HER2) have a poorer prognosis as compared to those that either do not make this protein or make lower levels [6]. It is important that overexpression of HER2 also identifies those women who may benefit from the targeted drug trastuzumab, and those who do better with chemotherapy regimens that contain a drug of the anthracycline class [6]. The humanized monoclonal antibody trastuzumab, which targets the human HER2, is an effective treatment for patients with HER2 overexpression, which comprises approximately 15–25% of all breast cancers [7, 8]. Meanwhile, capecitabine (N⁴-pentylloxycarbonyl-5'-deoxy-5-fluorocytidine), an orally administered prodrug of fluorouracil (FU), is also a highly active and well-tolerated treatment option for metastatic breast cancer. Capecitabine is the therapy specifically approved for anthracycline- and taxane-exposed patients, a setting that is becoming increasingly important as more patients have recurrent metastatic disease after receiving adjuvant anthracycline and taxane therapy [9–12]. The combination of capecitabine and trastuzumab might achieve improved efficacy in patients with HER2-positive metastatic breast cancer without compromising tolerability [13–15].

Recently, Schaller et al. [13] reported that the combination of capecitabine and trastuzumab is highly active in patients with HER2-overexpressing anthracycline- and/or taxane-pretreated breast cancer. However, to date, no studies

have investigated the activity of capecitabine and trastuzumab in patients with HER2-overexpressing breast cancer resistant to both anthracyclines and taxanes. In the present study, we evaluate the activity and safety of this two-agent combination therapy in patient, resistant to both anthracyclines and taxanes.

Patients and methods

Eligibility criteria

To be eligible for the study, patients had to meet the following criteria: age greater than 20 years and less than 75 years; histologically proven breast cancer with HER2 overexpressing progressive metastatic disease; resistance to both anthracyclines and taxanes for metastatic and advanced disease as described in below, resistance definition section; at least one measurable tumor site (target lesion) with index lesions on physical examination, X-ray, ultrasound, or computed tomography scan; Eastern Cooperative Oncology Group (ECOG) performance status of 0–2; estimated life expectancy ≥ 3 months; reasonable bone marrow function (neutrophil count $\geq 1,500/\mu\text{L}$, platelet count $\geq 100,000/\mu\text{L}$, and hemoglobin levels $\geq 9 \text{ g/dL}$); adequate hepatic and renal function, including AST and ALT twice (in cases of liver metastasis, three times) the upper limit of normal, bilirubin 1.5 g/dL, alkaline phosphatase 2.5 times the upper limit of normal, serum creatine 1.2 mg/dL, and basal creatine clearance 50 mL/min; no evidence of cardiac dysfunction (LV ejection fraction $> 50\%$). This capecitabine and trastuzumab combination regimen was eligible for patients in third line of therapy, resistant to both anthracyclines and taxanes. Hormonal therapy, in the neoadjuvant or adjuvant setting or for advanced disease, was permitted, but concomitant hormone therapy was not allowed. Moreover, prior trastuzumab was allowed. Brain or leptomeningeal involvement was not allowed. Written informed consent was obtained before registration. The HER2 status was assessed at study entry by immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH). Patients with HER2-receptor overexpression at the 3+ level (Hercep Test; DakoCytomation, Carpinteria, CA, USA) were immediately eligible for inclusion. A HER2 expression at the 2+ level required confirmation by the proof of a HER2 gene amplification by FISH. HER2 testing was performed on a sample of the primary tumor or a biopsy of a metastatic site. HER2 status was examined by the pathologists of each institution participated in this study. The FISH ratio was assessed as the number of genes proportional to the number of centromeres. The HER2 was considered amplified when the FISH signal ratio of HER2 was 2 and more. Exclusion criteria included pretreatment

with capecitabine (Xeloda; Hoffman La, Rosche AG); hypersensitivity to trastuzumab (Herceptin; Hoffman-La Rosche AG, Basel, Switzerland), fluoropyrimidines, capecitabine, or any other substance of the drug preparation; known lack of dihydropyrimidine dehydrogenase; local resection or irradiation of the marker lesion after study entry; additional systemic antitumor therapy study; pregnancy or breastfeeding.

All data were managed and analyzed in a central data coordinating division located at the Foundation for Biological Research and Innovation, Translational Research Informatics Center, Kobe, Japan.

Definition of both anthracycline and taxane resistance

We used Ando's definition [16] for reference to determine the primary resistance and secondary resistance to chemotherapeutic agents. All patients must not have received only anthracyclines, but also taxanes for metastatic disease. Primary resistance to anthracycline or taxane was defined as progressive disease during or within 6 months after completion of anthracycline or taxane, respectively. Patients without any documented tumor response to first-line chemotherapy that included anthracyclines or taxanes for metastatic disease also were classified as having primary resistance. Patients whose disease progressed more than 6 months after completion of anthracycline or taxane were treated as a first-line regimen for metastatic disease. Secondary resistance was defined as disease progression among 6–12 months after a documented clinical response to first-line chemotherapy with anthracyclines or taxanes for metastatic disease. Secondary resistance was further divided into three categories as follows: (a) absolute resistance: disease progression during treatment with regimens that contained anthracycline or taxane after a period after completion of the chemotherapy; (b) relative resistance: disease progression within 6 months after complete of the chemotherapy; and (c) sensitive regrowth: disease progression more than 12 months after completion of the chemotherapy.

Therapy

Trastuzumab was administered at an initial dose of 4 mg/kg body weight and was administered subsequently at weekly doses of 2 mg/kg body weight during 90 min. Capecitabine was administered during 21 days with a subsequent pause of 7 days. The daily dose was 1,657 mg/m² administered in equal parts in the morning and in the evening. This cycle was repeated every 28 days for six cycles. Trastuzumab was discontinued while capecitabine was held. When capecitabine was withdrawn, a new treatment cycle was considered. Trastuzumab and capecitabine were administered until disease progression or unacceptable toxicity.

If capecitabine-associated toxicity occurred, dosage reduction and delayed were permitted.

1. If a grade 2 toxicity occurred, the therapy was interrupted immediately until the symptoms disappeared completely. At that time, the medication was continued at a 75% level until six cycles. The level was never increased. If a grade 2 or 3 toxicity occurred again, this process was allowed once more until six cycles, at which point the medication was continued at a 50% level. The level was never increased. If a grade 4 toxicity occurred again, the therapy was interrupted immediately. The treatment was discontinued when the patient developed signs of toxicity for a third time.
2. At the beginning of the treatment, if a grade 3 toxicity occurred, the therapy was stopped immediately until the symptoms disappeared completely. At that time, the medication was continued at a 50% level until six cycles. The level was never increased. If a grade ≥ 2 toxicity occurred again, the treatment was discontinued.
3. At the beginning of the treatment, if a grade 4 toxicity occurred, the therapy was stopped immediately.

A dose modification of trastuzumab was not allowed. Mild antiemetic drugs, such as metoclopramide and dexamethasone, and mild antidiarrheal drugs, such as loperamide hydrochloride were administered, if necessary. Trastuzumab was discontinued if patients developed congestive heart failure or the LVEF fell below 45%. The decision to discontinue trastuzumab at that point was discussed with the patient after the risks and potential benefits of trastuzumab therapy were assessed. Granulocyte colony-stimulating factor, to prevent febrile neutropenia was allowed, if grade ≥ 3 leukopenia occurred, and blood or platelet transfusion was allowed, if grade ≥ 3 anemia or thrombocytopenia occurred.

Assessment

The pretreatment evaluation included medical history and physical examination, complete blood cell count, serum chemistries, liver function tests, ECG, echocardiography, tumor marker evaluation (CA15-3, CEA), hormone receptor status (ER, PgR, HER2), and staging studies appropriate to define the extent of metastatic disease, which included chest X-ray, abdominal ultrasound, brain, thoracic and/or abdominal computed tomography scan, and bone scan. Antitumor activity was evaluated every two cycles on all measurable lesions, and all patients were scheduled for at least a 2-week treatment to be eligible for assessment of tumor response. In patients with tumor response or stable disease, the treatment was planned to be continued for up to six cycles; thereafter, maintenance or no therapy was based

on the clinician's choice. After the completion of the treatment plan, the patients were monitored every two cycles. Clinical monitoring, complete blood cell count, serum chemistries, and liver function tests were performed every 2 weeks until six cycles, and thereafter every 12 weeks. Repeated multigated acquisition (MUGAs) or echocardiograms were performed after completion of cycle 2, 4, and 6, and thereafter every 12 weeks, if the medication is continued. Patients were evaluated for toxicity, graded according to the National Cancer Institute Common Toxicity Criteria version 2.0 [17].

Tumor response was evaluated according to the response evaluation criteria in solid tumors (RECIST) [18]. Progression-free survival was defined from the first day of treatment to the identification date of recurrence of cancer or death from any cause. Overall survival was dated from the first day of treatment until death or was censored on the date of the last follow-up appointment.

Statistical analysis

The primary endpoint of the study was the assessment of the overall survival. Secondary endpoints were the determination of the progression-free survival and response rate. In this trial, the targeted patients resistant to both anthracycline and taxane had highly dismal disease, whose 1 year survival was estimated <33% [16], thereby overall survival was chosen for the primary endpoint. The recent paper [19] reported that overall survival should be viewed as the endpoint of choice to assess the efficacy of new treatments in advanced breast cancer. The regimen would have been considered promising if the true 1-year survival were 50% or higher in conjunction with acceptable toxicity, and would be considered of no further interest if the true 1-year survival were 33% or lower. With 63 patients, the power of a two-sided 0.05-level test is 80%. However, the power was reduced to 62% because only 40 patients were enrolled in the study. Survival curves were estimated using the Kaplan–Meier method. To test the differences of the survival curves among subgroup of patients, the log-rank test was used. All statistical analyses were performed using the SAS version 9.1 (SAS Institute, Inc, Cary, NC, USA). All tests were two-sided, and a $P < 0.05$ was considered statistically significant.

Results

Patients characteristics

From June 2003 to May 2006, 40 patients with metastatic and HER2-overexpressing breast cancer, which was defined as the primary resistance or secondary resistance to


both anthracycline and taxane, were entered onto the study. One patient was declared ineligible after registration: one patient was treated off-protocol immediately after enrollment. Thirty-eight patients were reviewed extramurally and analyzed. The demographic data, numbers of metastatic tumor, and prior therapies are listed in Table 1. The median age was 53 years (range 30–69 years), and Eastern Cooperative Oncology Group performance status was good (0 or 1 in 95% of cases). Regarding prior treatments, 18 patients were given anthracycline as neoadjuvant or adjuvant chemotherapy and 19 patients for metastatic disease. In addition, 9 patients were given taxane as neoadjuvant or adjuvant chemotherapy and 28 patients for metastatic disease. Resistance to previous chemotherapies (anthracycline/taxane) was 7 patients (18%) with primary resistance/primary resistance, 11 with (29%) with primary/secondary, 6 (16%) with secondary/primary, 11 (29%) with secondary/secondary, and 3 (8%) with unknown, respectively. Predominate sites of metastasis were found in 37 cases (97%). 27 patients (71%) had one metastatic site, and 10 patients (26%) had multiple metastases involving two or more organ systems; 17 lung (45%), 10 liver (26%), 5 bone (13%), 2 skin (5%), and 4 other sites (10.5%), respectively. 34 (90%) of the patients had invasive ductal carcinomas, 3 patients (8%) had cancers of other types, but the histopathological type of one patient (3%) was unknown. Seventy nine percent of patients had a past history of prior therapy of trastuzumab.

Treatment activity

A median of 4.5 cycles (range 1–9 cycles) of treatment were delivered. The median dose of capecitabine was 227,400 mg/body (range 2,400–453,600 mg/body) and the median dose of trastuzumab was 1.28 mg/m²/week (range 0.31–1.51 mg/m²/week). Median follow-up time was 22.4 months (range 0.4–50.6 months). Median overall survival and progression-free survival of the entire group were 22.3 and 4.1 months, respectively (Fig. 1). Survival at 1 and 2 year was 81.6% (95% CI, 65.2–90.8%) and 47.4% (95% CI, 31.0–62.1%), respectively. The best responses recorded for each patient are listed in Table 2. A response rate (CR or PR) was recorded in 7 of 38 women (18.4%; 95% CI, 7.7–34%); 2 patients (5%) achieved a CR, and 5 patients (13%) achieved a PR. SD was observed in 20 patients (53%), and PD was observed in 8 (21%). Clinical benefit rate (CBR: CR or PR or SD \geq 24 weeks) was 21.1% (95% CI (confidence interval), 9.6–37.3%). All patients were treated previously with both anthracyclines and taxanes. According to the previous treatment, a tumor response was obtained in 18 (47%) of 38 cases previously submitted to anthracycline-containing regimens and in 22 (58%) of 38 cases submitted to taxane-containing regimens.

Table 1 Patient Characteristics

	No. of patients	%
No.	38	
Age, years		
Median	53	
Range	30–69	
Performance status ^a		
0	31	81.6
1	5	13.2
2	2	5.3
Menopausal status		
Premenopause	12	31.6
Postmenopause	26	68.4
Receptor status		
Estrogen receptor		
Positive	7	18.4
Negative	31	81.6
Progesterone receptor		
Positive	6	15.8
Negative	31	81.6
Unknown	1	2.6
Resistance to previous chemotherapies (Anthracycline/Taxane)		
Primary resistance/Primary resistance	7	18.4
Primary resistance/Secondary resistance	11	29.0
Secondary resistance/Primary resistance	6	15.8
Secondary resistance/Secondary resistance	11	29.0
Unknown	3	7.9
Prior trastuzumab		
Yes	30	78.9
No	8	21.2
Histology		
Invasive ductal carcinomas	34	89.5
Other	3	7.9
Unknown	1	2.6
Number of metastasis		
1	27	71.1
≥2	10	26.3
Unknown	1	2.6
Primary metastatic sites		
Lung	17	44.7
Liver	10	26.3
Bone	5	13.2
Skin	2	5.3
Peritoneum	1	2.6
Mediastinum	1	2.6
Pleura	1	2.6
Unknown	1	2.6

^a Eastern Cooperative Oncology Group**Fig. 1** Overall survival curve (solid line) and progression-free survival curve (dotted line) of patients with HFR2 overexpressing metastatic breast cancers with capecitabine and trastuzumab combination chemotherapy resistant to both anthracyclines and taxanes**Table 2** Response to therapy ($n = 38$)

Response	No. of Patients	%
Complete response	2	5.3
Partial response	5	13.2
Stable disease	20	52.6
Progressive disease	8	21.1
Not evaluated	3	7.9
Response rate	18.4% (95% CI, 7.7–34.3%)	
Clinical benefit rate (CBR = CR + PR + SD \geq 24 weeks)	21.1% (95% CI, 9.6–37.3%)	

CI confidence interval, CR complete response, PR partial response, SD stable disease for 6 weeks, PD progressive disease

13 (34%) or 10 (26%) of 38 patients had progressive disease during the treatment with anthracyclines or taxanes, respectively. There was no difference in overall survival in patients with and without history of trastuzumab ($P = 0.80$).

Anthracycline or taxane resistance and response to capecitabine and trastuzumab combination chemotherapy

The response rates of patients with primary and secondary resistance of anthracycline and taxane are shown in Table 3. There was no difference in response rate between primary and secondary resistance in anthracycline and taxane pretreated patients, respectively ($P = 0.73$).

Toxicity

Associated side effects are reported in Table 4; on the whole, they were mild. There were no treatment-related deaths. Regarding the hematological toxicities, neutropenia occurred in 19 patients but was grade 3 only in 2 patients (5%). Thrombocytopenia was rather uncommon, occurring

Table 3 Response rates classified by anthracycline or taxane resistance category

Anthracycline/ Taxane	Primary resistance/ Primary resistance	Primary resistance/ Secondary resistance	Secondary resistance/ Primary resistance	Secondary resistance/ Secondary resistance
No. of patients	7	11	6	11
Response rate (%)	1/7 (14.3)	2/11(18.2)	2/6 (33.3)	1/11(9.1)
95% CI	0.4–57.9	2.3–51.8	4.3–77.7	0.2–41.3

C Confidence interval. There was no difference in response rate among each group ($P = 0.73$)

(grade 1) in only two case (5%). Seven patients developed grade 2 anemia (18%). Grade ≥ 4 hematologic toxicity was not observed. No patient developed a documented infection, and none required hospitalization owing to toxicity. Moreover, grade 1/2 liver dysfunction (elevated AST, ALT, ALP, γ -GTP, and T-bil) was common (45, 34, 50, 34, and 42%), and grade 1/2 hypercalcemia and hypoalbuminemia was also common (45 and 32%). Regarding the nonhematological toxicities, the most common adverse events were hand-foot syndrome (grade 1/2/3 in 24; 63%), fatigue (grade 1/2 in 12; 32%), and diarrhea (grade 1/2/3 in 9; 24%). Mucositis occurred in 11 patients (grade 1 in 10; 29%). Serious adverse effects occurred in three patients (7.9%, 95% CI, 1.7–21.4%): 2 died of breast cancer and one died of accidental asphyxia. Twenty-three patients discontinued therapy because of disease progression in 13, physician's discretion in 4, adverse effects in 4 (grade 3 neutropenia at cycle 2, grade 2 general fatigue at cycle 2, and grade 3 hand-foot syndrome at cycle 2 and 5), and death in 2.

Discussion

We have detected three reports concerning the activity of capecitabine and trastuzumab in anthracyclines or taxanes-pretreated patients with HER2-overexpressing breast cancer [13–15]. However, there is no prospective study describing the activity of capecitabine and trastuzumab in patients with HER2-overexpressing breast cancer resistant to both anthracyclines and taxanes. This is the first report that the combination of capecitabine and trastuzumab is active in patients with HER2-overexpressing breast cancer resistant to both anthracycline and taxane. Moreover, we could observe that among the patients with the primary and secondary resistant to anthracycline and taxane, there was no difference in response rate.

In recent studies of various chemotherapeutic agents for breast cancer patients after failure of both anthracycline and taxanes, the median overall survival was 12.8 months with capecitabine alone [8], 7.8 months with gemcitabine alone [20], 7.4 months with gemcitabine and cisplatin [21], and 10.3 months with gemcitabine and pemetrexed [22]. In the

present study, we suggested that the median overall survival was prolonged to 22.3 months with the combination of capecitabine and trastuzumab for patients resistant to both anthracyclines and taxanes. Therefore, we speculate that trastuzumab with capecitabine can increase the overall survival in patients with these HER2 overexpressing metastatic breast cancers. For such category of patients, one phase II study of trastuzumab plus gemcitabine in both anthracycline and taxane-pretreated patients with metastatic breast cancer, the median overall survival was reported to be 14.7 months [23]. Further, Fig. 1 shows that 79% of the patients enrolled in the present study had a past history of trastuzumab administration. Very recently, Minckwitz et al. [24] reported a higher efficacy for continuing trastuzumab beyond trastuzumab progression when second-line chemotherapy with capecitabine was initiated.

Until recently relative few clinical data were available concerning the combination of trastuzumab with capecitabine. Osako et al. [14] retrospectively evaluated the efficacy and safety of combination therapy of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer. They investigated objective response rate, clinical benefit rate, and time-to-treatment failure according to RECIST. A total of 49 patients were assessed and median follow-up time of patients was 16.2 months (1.4–43.5 months). Objective response rate was 16% (95% CI: 7–30%) and clinical benefit rate was 47% (95% CI: 32–62%). Median time-to-treatment failure was 5.4 months. Osako's report suggests the combination therapy of trastuzumab plus capecitabine was active and tolerable for heavily pretreated patients with HER2-positive metastatic breast cancer. The combination therapy with capecitabine and trastuzumab has been used by the other investigators as a first-line [25] or second-line [13] treatment for metastasis from breast cancer. Patients receiving trastuzumab and capecitabine as first-line therapy had a longer time to disease progression than did patients receiving this treatment as second- or third-line therapy (median time to disease progression, 9.3 vs. 6.7 months, $P < 0.05$), but did not have longer overall survival (median overall survival, 26.0 vs. 28.0 months).

As to the toxicities of the combination therapy with capecitabine and trastuzumab, Schaller et al. [13] reported

Table 4 Toxicity results

Toxicity grade ^a	Grade 1	Grade 2	Grade 3	Grade 4
	No. of patients (%)	No. of patients (%)	No. of patients (%)	No. of patients (%)
Hematological toxicity				
Anemia	1 (2.6)	7 (18.4)	0	0
Leucocytopenia	1 (2.6)	6 (15.8)	0	0
Neutropenia	11 (28.9)	6 (15.8)	2 (5.3)	0
Thrombocytopenia	2 (5.3)	0	0	0
Elevated ALP	17 (44.7)	2 (5.3)	0	0
Elevated AST	14 (36.8)	3 (7.9)	0	0
Elevated ALT	12 (31.6)	1 (2.6)	0	0
Elevated γ -GTP	8 (21.1)	3 (7.9)	2 (5.3)	0
Elevated T-Bil	11 (28.9)	5 (13.2)	0	0
Elevated creatinine	1 (2.6)	0	0	0
Hypercalcemia	16 (42.1)	1 (2.6)	0	0
Hypoalbuminemia	12 (31.6)	0	0	0
Nonhematological toxicity				
Hand-foot syndrome	16 (42.1)	5 (13.2)	3 (7.9)	0
Mucositis	11 (28.9)	0	0	0
Nausea	8 (21.1)	0	0	0
Vomiting	4 (10.5)	0	0	0
Diarrhea	7 (18.4)	1 (2.6)	1 (2.6)	0
Constipation	0	0	1 (2.6)	0
Abdominal pain	1 (2.6)	0	0	0
Edema	3 (7.9)	0	0	0
Rash	1 (2.6)	0	0	0
Hyperpigmentation	5 (13.2)	0	0	0
Pruritus	1 (2.6)	0	0	0
Injection site reaction	1 (2.6)	0	0	0
Nail changes	1 (2.6)	1 (2.6)	0	0
Ulceration	1 (2.6)	0	0	0
Cervical pain	1 (2.6)	0	0	0
Chest pain	2 (5.3)	0	0	0
Cough	2 (5.3)	1 (2.6)	0	0
Sputum	0	1 (2.6)	0	0
Dyspnea	0	1 (2.6)	0	0
Fever	3 (7.9)	1 (2.6)	0	0
Fatigue	10 (26.3)	2 (5.3)	0	0
Appetite loss	2 (5.3)	1 (2.6)	0	0
Weight loss	0	1 (2.6)	0	0
Headache	5 (13.2)	0	0	0
Dizziness	1 (2.6)	0	0	0
Voice changes	1 (2.6)	0	0	0
Impaired motor function	4 (10.5)	0	0	0
Photophobia	0	1 (2.6)	0	0
Cataract	0	1 (2.6)	0	0
Back pain	1 (2.6)	0	0	0
Urinary retention	1 (2.6)	0	0	0
Pain on urination	1 (2.6)	0	0	0

^a According to National Cancer institute common Toxicity Criteria

that the safety profile of this combination was favorable for breast cancer patients with HER2-overexpressing anthracycline- and/or taxane-pretreated breast cancer. The most common adverse events were pain, hand-foot syndrome, and gastrointestinal toxicities. In the present study, we confirmed that this combination therapy was safe and well tolerated regimen. Moreover, the present study suggested that grade 1/2 liver dysfunction (elevated AST, ALT, ALP, γ -GTP, and T-bil) was common in the combination therapy of capecitabine and trastuzumab. As to the hematological toxicities, grade 1/2 anemia occurred in 21% patients in the present trial versus 68% in Schaller's trial, but grade 3/4 anemia in 5% versus 8% patients. Moreover, regarding the nonhematological toxicities, grade 1/2 hand-foot syndrome, one of the most common adverse events, occurred in 55% patients in this present trial versus 68% in Schaller's trial, but grade 3/4 in 8 versus 16% patients. Because it was reported that no clinically relevant differences in the pharmacokinetics of capecitabine and its key metabolites 5'-DFUR, 5'-DFCR, and 5-FU were found between Japanese and Caucasian patients [26], the lower incidence of toxicity observed in our study may be due to the difference of total doses of capecitabine between the present trial and Schaller's trial: the total dose of the present trial [about 156,586 mg/m²: 1,657 mg/m² × 21 days × 4.5 (median treatment cycles)] versus that of Schaller's trial (about 280,000 mg/m²: 2,500 mg/m² × 14 days × 8 (median treatment cycles)). The reason why we selected a dose 1,657 mg/m²/day during 21 days with a subsequent pause of 7 days as given capecitabine was rigorously based on the previous result in Japan [27]. There were no differences in response rate (20 vs. 20%) and median time to disease progression (2.8 vs. 3.0 months) between the different drug administrations from Japan and US [8, 27]. Consistent with this, further investigations are needed to assess the safety in additional clinical trials.

In conclusion, the combination of capecitabine and trastuzumab is active and well-tolerated in patients with HER2-overexpressing breast cancer well defined resistance to both anthracyclines and taxanes. Although at present, the other chemotherapeutic agents such as vinorelbine and oxaliplatin are under way for such category group disease [28], our results suggest that this combination therapy may be established as a third line chemotherapy for these breast cancer patients, by using the overall survival as primary endpoint and the progression-free survival and response rate as secondary endpoints, because the targeted patients in the present study had highly dismal disease.

Acknowledgments We thank Keiko Miyakoda and Tomomi Sakabayashi (Translational Research Informatics Center, Kobe, Japan) for their statistical review and advice.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Appendix

The following individuals and institutions participated in this study: N. Ohuchi, MD, T. Ishida, MD, M. Takeda, MD, Tohoku University Hospital, Sendai, Japan; Y. Takatsuka, MD, T. Aihara, MD, Kansai Rosai Hospital, Amagasaki, Japan; N. Masuda, MD, Osaka National Hospital, Osaka, Japan; S. Noguchi, MD, T. Taguchi, MD, Osaka University Hospital, Suita, Japan; R. Nishimura, MD, Kumamoto City Hospital, Kumamoto, Japan; G. Armano, MD, Sakata City Hospital, Sakata, Japan; M. Tamura, MD, M. Takehara, MD, Hokkaido Cancer Center, Sapporo, Japan; T. Ohmura, MD, Sapporo Medical University Hospital, Sapporo, Japan; Y. Narita, MD, Teine Keijinkai Hospital, Sapporo, Japan; M. Kashiwaba, MD, Iwate Medical University Hospital, Morioka, Japan; Y. Kiyosawa, MD, Nakadori General Hospital, Akita, Japan; T. Hashizume, MD, Akita City Hospital, Akita, Japan; S. Kimura, MD, M. Kamiga MD, Yamagata University Hospital, Yamagata, Japan; A. Kikuchi, MD, S. Kudo MD, Yamagata Prefectural Central Hospital, Yamagata, Japan; H. Hirakawa, MD, A. Tazawa MD, Tohoku Kosai Hospital, Sendai, Japan; K. Namiki, MD, R. Yoshida, MD, Osaki Citizen Hospital, Osaki, Japan; T. Nomizu MD, Hoshi General Hospital, Koriyama, Japan; E. Fukuma, MD, Kameda General Hospital, Kamogawa, Japan; N. Yamamoto, MD, Chiba Cancer Center, Chiba, Japan; M. Toi, MD, S. Saji MD, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan; H. Tahara, MD, Y. Takeda, MD, Institute of Medical Science, University of Tokyo, Tokyo, Japan; S. Nakamura, MD, St. Luke's International Hospital, Tokyo, Japan; M. Kusama, MD, Tokyo Medical University Hospital, Tokyo, Japan; T. Asaga, MD, M. Inaba, MD, Kanagawa Cancer Center, Yokohama, Japan; M. Fukuda, MD, H. Ogata, MD, St. Marianna University Hospital, Kawasaki, Japan; K. Iwase, MD, Fujita Health University Hospital, Toyoake, Japan; H. Yoshino, MD, Ishikawa Prefectural Central Hospital, Kanazawa, Japan; E. Shiba, MD, Osaka Kosei Nenkin Hospital, Osaka, Japan; J. Matsuoka, MD, Okayama University Hospital, Okayama, Japan; S. Murakami, MD, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; S. Mitsuyama, MD, Kitakyushu Municipal Medical Center, Kitakyushu, Japan.

References

1. Ueno M, Kiba T, Nishimura T et al (2007) Changes in survival during the past two decades for breast cancer at the Kyoto University Hospital. *Eur J Surg Oncol* 33:696–699

2. Petrelli F, Cabiddu M, Cazzaniga ME et al (2008) Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. *Oncologist* 13:373–381
3. Beslija S, Bonnetterre J, Hurstein H et al (2007) Second consensus on medical treatment of metastatic breast cancer. *Ann Oncol* 18:215–225
4. Ueno NT, Buzdar AU, Singletary SE (1997) Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. *Cancer Chemother Pharmacol* 40:321–329
5. Berg CD, Swain SM (1994) Results of concomitantly administered chemoradiation for locally advanced noninflammatory breast cancer. *Semin Radiat Oncol* 4:226–235
6. http://www.uptodate.com/patients/content/topic.do?topic_key=cancer/2904
7. Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER-2 and its role in cancer. *Biochim Biophys Acta* 1198:165–184
8. Revillion F, Bonnetterre J, Peyrat JP (1998) ERBB2 oncogene in human breast cancer and its clinical significance. *Eur J Cancer* 34:791–808
9. Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. *J Clin Oncol* 17:485–493
10. Blum JL, Dieras V, Lo Russo PM et al (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. *Cancer* 92:1759–1768
11. Reichardt P, Von Minckwitz G, Thuss-Patience PC et al (2003) Multicenter phase II study of oral capecitabine (Xeloda™) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. *Ann Oncol* 14:1227–1233
12. Fumoleau P, Largillier R, Clippe C et al (2004) Multicenter, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. *Eur J Cancer* 40:536–542
13. Schaller G, Fuchs I, Gonsch T et al (2007) Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. *J Clin Oncol* 25:3246–3250
14. Osako T, Ito Y, Takahashi S et al (2008) Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer. *Cancer Chemother Pharmacol* 62:159–164
15. Bartsch R, Wenzel C, Altorjai G et al (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. *J Clin Oncol* 25:3853–3858
16. Ando M, Watanabe T, Nagata K et al (2001) Efficacy of docetaxel 60 mg/m² in patients with metastatic breast cancer according to the status of anthracycline resistance. *J Clin Oncol* 19:336–342
17. http://ctep.cancer.gov/forms/CTCv20_4_30-992.pdf
18. Therasse P, Arbuuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92:205–216
19. Burzykowski T, Buyse M, Piccart-Gebhart MJ et al (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. *J Clin Oncol* 26:1987–1992
20. Smorenburg CH, Bontenbal M, Seynaeve C et al (2001) Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. *Breast Cancer Res Treat* 66:83–87
21. Tax F, Guney N, Derin D et al (2008) Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer. *Invest New Drugs* 26:363–368
22. Ma CX, Steen P, Rowland KM et al (2006) A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. *Ann Oncol* 17:226–231
23. O'Shaughnessy JA, Vukelja S, Marsland T et al (2004) Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. *Clin Breast Cancer* 5:142–147
24. Minckwitz G, Zielinski C, Maarteens E et al (2008) Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). *J Clin Oncol* 26:1025a
25. Xu L, Song S, Zhu J et al (2004) Results of a phase II trial of Herceptin plus Xeloda in patients with previously untreated HER2-positive metastatic breast cancer. *Breast Cancer Res Treat* 88(suppl 1):S128
26. Reigner B, Watanabe T, Schüller J et al (2003) Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer. *Cancer Chemother Pharmacol* 52:193–201
27. Watanabe T, Katsumata N, Sasaki Y et al (1991) A multicenter phase II Trial of Xeloda™ (Capecitabine) in patients with docetaxel-refractory advanced/metastatic breast cancer. *Proc Am Soc Clin Oncol* 20:1991a
28. <http://www.clinicaltrials.gov>